Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS

Tarsus Pharmaceuticals Stock Analysis & Ratings

TARS Stock Chart & Stats

Day’s Range$13.36 - $14
52-Week Range$10.80 - $39.08
Previous Close$13.41
Volume81.26K
Average Volume (3M)115.03K
Market Cap$360.68M
P/E Ratio-6.3
Beta1.45
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-2.17


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

TARS FAQ

What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $10.80 and its highest was $39.08 in the past 12 months.
    What is Tarsus Pharmaceuticals’s market cap?
    Tarsus Pharmaceuticals’s market cap is $360.68M.
      What is Tarsus Pharmaceuticals’s price target?
      The average price target for Tarsus Pharmaceuticals is $52.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $65.00 ,the lowest forecast is $40.00. The average price target represents 283.21% Increase from the current price of $13.7.
        What do analysts say about Tarsus Pharmaceuticals?
        Tarsus Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Tarsus Pharmaceuticals’s upcoming earnings report date?
          Tarsus Pharmaceuticals’s upcoming earnings report date is Aug 03, 2022 which is in 74 days.
            How were Tarsus Pharmaceuticals’s earnings last quarter?
            Tarsus Pharmaceuticals released its earnings results on May 10, 2022. The company reported -$0.98 earnings per share for the quarter, missing the consensus estimate of -$0.903 by -$0.077.
              Is Tarsus Pharmaceuticals overvalued?
              According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued.
                Does Tarsus Pharmaceuticals pay dividends?
                Tarsus Pharmaceuticals does not currently pay dividends.
                What is Tarsus Pharmaceuticals’s EPS estimate?
                Tarsus Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Tarsus Pharmaceuticals have?
                Tarsus Pharmaceuticals has 26,330,000 shares outstanding.
                  What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
                  Tarsus Pharmaceuticals reported an EPS of -$0.98 in its last earnings report, missing expectations of -$0.903. Following the earnings report the stock price went down -3.677%.
                    Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
                    Among the largest hedge funds holding Tarsus Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Tarsus Pharmaceuticals’s shares valued at 22M.

                      ---

                      Tarsus Pharmaceuticals Stock Analysis

                      The Tarsus Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Tarsus Pharmaceuticals

                      Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.

                      ---
                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis